Related Experiment Videos
Potential genetic risks of using semen collected during chemotherapy
1Department of Experimental Radiotherapy, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Human Reproduction (Oxford, England)
|January 1, 1993
Summary
Semen cryopreserved during chemotherapy poses genetic risks to offspring. Patients should freeze sperm before treatment and use contraception for six months post-treatment to avoid mutagenic effects.
Area of Science:
- Reproductive toxicology
- Genetics
- Oncology
Background:
- Chemotherapy and radiation can induce mutagenic effects in germ cells.
- Previous recommendations suggested safe insemination using cryopreserved semen from treated males.
- Concerns exist regarding potential genetic damage to offspring.
Purpose of the Study:
- To evaluate the safety of using semen cryopreserved during chemotherapy for insemination.
- To assess the genetic risks to offspring resulting from conception during or shortly after male-patient treatment.
- To provide updated recommendations for fertility preservation and contraception in patients undergoing chemotherapy.
Main Methods:
- Review of experimental animal data on mutagenic effects in offspring.
- Analysis of studies on the impact of mutagens on testicular germ cells.
- Discussion of the relevance of animal data to human reproductive health.
Main Results:
- Studies indicate a significant potential for genetic risk to offspring.
- Experimental animal data show high levels of mutagenic effects in offspring from matings during or soon after male treatment.
- Existing recommendations regarding the safety of insemination with cryopreserved semen from treated males are challenged.
Conclusions:
- Using semen cryopreserved during chemotherapy for insemination is not safe due to potential genetic risks.
- Patients should complete semen cryopreservation before chemotherapy initiation.
- Reliable contraception is recommended from treatment initiation until six months after completion.